Stay updated with breaking news from Deep Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deep Pharma Intelligence released a special report “Artificial Intelligence in Drug Discovery: Focus on Oncology (Q2 2021)”, which builds on the previous
Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is
Exscientia. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive royalties on net sales of any marketed drug products resulting from the collaboration. The biotech industry is increasingly using AI to deploy targeted drug molecules to test the efficacy of drugs to tackle illnesses ranging from cancer to heart disease. Headquarters of Bristol-Myers Squibb Germany in Munich, G...